1. Home
  2. NTRB vs ELTX Comparison

NTRB vs ELTX Comparison

Compare NTRB & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRB
  • ELTX
  • Stock Information
  • Founded
  • NTRB 2016
  • ELTX 2011
  • Country
  • NTRB United States
  • ELTX United States
  • Employees
  • NTRB N/A
  • ELTX N/A
  • Industry
  • NTRB Industrial Specialties
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NTRB Health Care
  • ELTX Health Care
  • Exchange
  • NTRB Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • NTRB 77.9M
  • ELTX 49.7M
  • IPO Year
  • NTRB N/A
  • ELTX 2021
  • Fundamental
  • Price
  • NTRB $6.17
  • ELTX $4.16
  • Analyst Decision
  • NTRB
  • ELTX Buy
  • Analyst Count
  • NTRB 0
  • ELTX 2
  • Target Price
  • NTRB N/A
  • ELTX $10.00
  • AVG Volume (30 Days)
  • NTRB 28.2K
  • ELTX 16.1K
  • Earning Date
  • NTRB 12-11-2024
  • ELTX 11-07-2024
  • Dividend Yield
  • NTRB N/A
  • ELTX N/A
  • EPS Growth
  • NTRB N/A
  • ELTX N/A
  • EPS
  • NTRB N/A
  • ELTX N/A
  • Revenue
  • NTRB $1,803,816.00
  • ELTX N/A
  • Revenue This Year
  • NTRB N/A
  • ELTX N/A
  • Revenue Next Year
  • NTRB N/A
  • ELTX N/A
  • P/E Ratio
  • NTRB N/A
  • ELTX N/A
  • Revenue Growth
  • NTRB N/A
  • ELTX N/A
  • 52 Week Low
  • NTRB $1.93
  • ELTX $2.96
  • 52 Week High
  • NTRB $9.60
  • ELTX $11.45
  • Technical
  • Relative Strength Index (RSI)
  • NTRB 50.57
  • ELTX 40.82
  • Support Level
  • NTRB $5.24
  • ELTX $4.05
  • Resistance Level
  • NTRB $6.40
  • ELTX $4.89
  • Average True Range (ATR)
  • NTRB 0.71
  • ELTX 0.28
  • MACD
  • NTRB -0.12
  • ELTX -0.06
  • Stochastic Oscillator
  • NTRB 33.23
  • ELTX 27.37

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: